Redefining the asthma treatment paradigm using a locally administered dual PI3Kgd inhibitor
Matt Thomas (Gothenburg, Sweden), Matt Thomas, Peter Bold, Karin Bjorhall, Andrew Butcher, Johan Carlsson, Paulina Cygan, Maria Karlsson, Helena Lindmark, Rose Maciewicz, Mickael Mogemark, Vikki Morrison, Maria Nordberg, Matthew Perry, Sandra Rodrigo Blomqvist, Carla Winkler, Carl Goodyear, Kostas Karabelas
Source: International Congress 2016 – New therapies and therapeutic targets
Session: New therapies and therapeutic targets
Session type: Oral Presentation
Number: 468
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Matt Thomas (Gothenburg, Sweden), Matt Thomas, Peter Bold, Karin Bjorhall, Andrew Butcher, Johan Carlsson, Paulina Cygan, Maria Karlsson, Helena Lindmark, Rose Maciewicz, Mickael Mogemark, Vikki Morrison, Maria Nordberg, Matthew Perry, Sandra Rodrigo Blomqvist, Carla Winkler, Carl Goodyear, Kostas Karabelas. Redefining the asthma treatment paradigm using a locally administered dual PI3Kgd inhibitor. Eur Respir J 2016; 48: Suppl. 60, 468
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
New outlook on the Th1/Th2-alternative signaling pathways in asthma Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013
Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Applying the 3Rs to asthma research Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Antioxidant efficiency in the treatment of asthma exacerbations Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
ALX-0962, an anti-IgE Nanobody® with a dual mode of action Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Different roles for PI3Kgamma and δ in asthma Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014
Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Chronic dosing effects of propranolol in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Lung specific induction of Wnt-1 has a prophylactic and therapeutic effect on the development of an allergic airway disease Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013
B cells in a murine model of allergic asthma and respiratory tolerance Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015